Literature DB >> 16572872

Guillain-Barré syndrome as a cause of reversible cardiomyopathy.

Jason S Finkelstein1, Bekir H Melek.   

Abstract

Although autonomic dysfunction is a common manifestation of Guillain-Barré syndrome, cardiovascular involvement in this setting has rarely been reported in the literature. We describe a case of reversible left ventricular systolic dysfunction in a 60-year-old man with Guillain-Barré syndrome. Our patient had no history or signs of cardiac dysfunction on initial presentation. During the clinical manifestation of his autonomic dysfunction, he developed electrocardiographic changes accompanied by mildly elevated cardiac enzymes and severe left ventricular systolic dysfunction and segmental wall motion abnormality, which coincided with elevated urinary catecholamine and vanilmandelic acid levels. These abnormalities, and his symptoms, resolved rapidly once the acute episode was over. We believe the reversible left ventricular dysfunction was due to the toxic effect of increased catecholamines and to the transiently damaged sympathetic nerve endings in the myocardium, presumably a consequence of Guillain-Barré syndrome. We recommend that echocardiography be performed in patients with clinical signs of autonomic dysfunction, especially if they are associated with abnormal electrocardiographic findings, cardiac enzyme elevation, or hemodynamic instability, so that appropriate medical therapy can be instituted in a timely manner.

Entities:  

Mesh:

Year:  2006        PMID: 16572872      PMCID: PMC1413614     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  8 in total

1.  Neurogenic stunned myocardium in Guillain-Barré syndrome.

Authors:  R Bernstein; S A Mayer; A Magnano
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

2.  'Voodoo' death revisited: the modern lessons of neurocardiology.

Authors:  Martin A Samuels
Journal:  Cleve Clin J Med       Date:  2007-02       Impact factor: 2.321

3.  Autonomic function in demyelinating and axonal subtypes of Guillain-Barré syndrome.

Authors:  M Asahina; S Kuwabara; A Suzuki; T Hattori
Journal:  Acta Neurol Scand       Date:  2002-01       Impact factor: 3.209

4.  Estimation of plasma and urinary catecholamines in Guillain-Barré syndrome.

Authors:  J Ahmad; A S Kham; M A Siddiqui
Journal:  Jpn J Med       Date:  1985-02

5.  [A patient with Guillain-Barré syndrome and recurrent episodes of ST elevation and left ventricular hypokinesis in the anterior wall].

Authors:  Akiyuki Hiraga; Kiyomi Nagumo; Koji Suzuki; Yumi Sakakibara; Shigeyuki Kojima
Journal:  No To Shinkei       Date:  2003-06

6.  Autonomic dysfunction in the Guillain-Barré syndrome. Hemodynamic and neurobiochemical studies.

Authors:  A Durocher; B Servais; M Caridroix; C Chopin; F Wattel
Journal:  Intensive Care Med       Date:  1980       Impact factor: 17.440

7.  Reversible left ventricular dysfunction associated with Guillain-Barré syndrome--an expression of catecholamine cardiotoxicity?

Authors:  K Iga; Y Himura; C Izumi; T Miyamoto; K Kijima; H Gen; T Konishi
Journal:  Jpn Circ J       Date:  1995-04

8.  Assessment of autonomic dysfunction in Guillain-Barré syndrome and its prognostic implications.

Authors:  N K Singh; A K Jaiswal; S Misra; P K Srivastava
Journal:  Acta Neurol Scand       Date:  1987-02       Impact factor: 3.209

  8 in total
  3 in total

1.  Intrapulmonary right-left shunts in Guillain-Barré syndrome with severe dysautonomia.

Authors:  Marek Sykora; Jennifer Diedler; Werner Hacke; Roland Veltkamp
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 2.  Reversible Cardiomyopathies.

Authors:  Harsh Patel; Raef Madanieh; Constantine E Kosmas; Satya K Vatti; Timothy J Vittorio
Journal:  Clin Med Insights Cardiol       Date:  2015-05-21

3.  Guillain-Barré syndrome complicated by takotsubo cardiomyopathy: an under-recognised association.

Authors:  Timothy Jones; Neelan Umaskanth; James De Boisanger; Henry Penn
Journal:  BMJ Case Rep       Date:  2020-02-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.